Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Epigenomics|June 13, 2024
Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitorsMin Kyung Lee, Ze Zhang, Kartik Sehgal, et al.
Nature Communications|December 8, 2017
Human CD26<sup>high</sup> T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistenceStefanie R Bailey, Michelle H Nelson, Kinga Majchrzak, et al.
Practical Laboratory Medicine|July 3, 2020
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor BoardErica B Bernhardt, Mary D Chamberlin, Ivan P Gorlov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid TumorsCarolyn D Britten, Elizabeth Garrett-Mayer, Steven H Chin, et al.
Journal of Clinical Pharmacology|December 31, 2013
The effects of a high-fat meal on single-dose vemurafenib pharmacokineticsAntoni Ribas, Weijiang Zhang, Ilsung Chang, et al.
Nature Cancer|June 28, 2021
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapyJichang Han, Yanding Zhao, Keisuke Shirai, et al.
Cancer Immunology, Immunotherapy : CII|December 24, 2025
A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancerMd Saiful Islam Saif, Kartik Sehgal, Ze Zhang, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
CD39 is expressed on functional effector and tissue resident memory CD8+ T cellsJordan F Isaacs, Hanna N Degefu, Tiffany Chen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 8, 2024
CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T CellsJordan F Isaacs, Hanna N Degefu, Tiffany Chen, et al.
Journal for Immunotherapy of Cancer|November 9, 2024
Depletion of conventional CD4<sup>+</sup> T cells is required for robust priming and dissemination of tumor antigen-specific CD8<sup>+</sup> T cells in the setting of anti-CD4 therapyDelaney E Ramirez, Christo P C Dragnev, Tyler G Searles, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Epigenomics|June 13, 2024
Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitorsMin Kyung Lee, Ze Zhang, Kartik Sehgal, et al.
Nature Communications|December 8, 2017
Human CD26<sup>high</sup> T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistenceStefanie R Bailey, Michelle H Nelson, Kinga Majchrzak, et al.
Practical Laboratory Medicine|July 3, 2020
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor BoardErica B Bernhardt, Mary D Chamberlin, Ivan P Gorlov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2017
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid TumorsCarolyn D Britten, Elizabeth Garrett-Mayer, Steven H Chin, et al.
Journal of Clinical Pharmacology|December 31, 2013
The effects of a high-fat meal on single-dose vemurafenib pharmacokineticsAntoni Ribas, Weijiang Zhang, Ilsung Chang, et al.
Nature Cancer|June 28, 2021
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapyJichang Han, Yanding Zhao, Keisuke Shirai, et al.
Cancer Immunology, Immunotherapy : CII|December 24, 2025
A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancerMd Saiful Islam Saif, Kartik Sehgal, Ze Zhang, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
CD39 is expressed on functional effector and tissue resident memory CD8+ T cellsJordan F Isaacs, Hanna N Degefu, Tiffany Chen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 8, 2024
CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T CellsJordan F Isaacs, Hanna N Degefu, Tiffany Chen, et al.
Journal for Immunotherapy of Cancer|November 9, 2024
Depletion of conventional CD4<sup>+</sup> T cells is required for robust priming and dissemination of tumor antigen-specific CD8<sup>+</sup> T cells in the setting of anti-CD4 therapyDelaney E Ramirez, Christo P C Dragnev, Tyler G Searles, et al.
Pageof 9